This study involves a number of different medications.
The first is called “Autogene Cevumeran” (RO7198457), which is an experimental cancer therapy similar to a vaccine. This drug works by “teaching” your immune system how to fight off cancer cells using an injection of harmless tumour material. Since this treatment is not yet approved by Health Canada, it currently has the placeholder name RO7198457.
The other drug in this study is called Atezolizumab (Tecentriq®), which is a Health Canada-approved immunotherapy treatment for kidney cancer. Atezolizumab works by reactivating the body’s own immune response to target and destroy cancer cells.
This study will investigate the safety and effectiveness of RO7198457 given either by itself, or in combination with Atezolizumab. You will be randomly assigned to one of these two groups.
Different doses of RO7198457 will be used to determine the optimal dosage.
- Clear cell kidney cancer (incl. sarcomatoid features)
- Cancer has spread or cannot be removed by surgery
- Must have received at least one other treatment for kidney cancer
- No previous treatment with immunotherapy
Additional eligibility criteria will apply. Please speak to your doctor.
Find out more about this study.
|Hospital / Cancer Centre||Principal Investigator||Location||Trial Status|
|Hospital / Cancer CentreOttawa Hospital Cancer Centre||Principal Investigator||LocationOttawa, ON||Trial StatusRecruiting|
|Hospital / Cancer CentrePrincess Margaret Cancer Centre||Principal InvestigatorDr. Lillian Siu||LocationToronto, ON||Trial StatusRecruiting|